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ABSTRACT
Objective: To identify the viruses involved in acute 
respiratory tract infections and to analyze the rates of hospi-
talization and death in children on palivizumab prophylaxis.
Methods: Prospective cohort of 198 infants up to one 
year old who were born before 29 weeks  of gestational age 
and infants under two years old with hemodynamically 
unstable cardiopathy or chronic pulmonary disease who 
received prophylactic palivizumab against severe respira-
tory syncytial virus infections in 2008. During the study 
period, in each episode of acute respiratory tract infection, 
nasopharyngeal aspirate was collected to identify respiratory 
syncytial virus, adenovirus, parainfluenza 1, 2 and 3, influ-
enza A and B by direct immunofluorescence, rhinovirus and 
metapneumovirus by polymerase chain reaction preceded 
by reverse transcription. Data regarding hospitalization and 
deaths were monitored.
Results: Among the 198 studied infants, 117 (59.1%) 
presented acute respiratory tract infections, with a total 
of 175 episodes. Of the 76 nasopharyngeal aspirates col-
lected during respiratory tract infections, 37 were positive, 
as follow: rhinovirus (75.7%), respiratory syncytial virus 
(18.9%), parainfluenza (8.1%), adenovirus 2 (2.7%), meta-
pneumovirus (2.7%) and three samples presented multiple 
agents. Of the 198 children, 48 (24.4%) were hospitalized: 
30 (15.2%) for non-infectious etiology and 18 (9.1%) for 
respiratory causes. Among these 18 children, one case of re-
spiratory syncytial virus was identified. Two deaths were 
reported, but respiratory syncytial virus was not identified. 
Conclusions: During the prophylaxis period, low fre-
quency of respiratory syncytial virus infections and low rates 
of hospitalization were observed, suggesting the benefit of 
palivizumab prophylaxis.  
Key-words: respiratory syncytial viruses; antibodies, 
monoclonal; respiratory tract infections/prevention & 
control; infant.
RESUMO
Objetivo: Identificar os vírus envolvidos nos quadros de 
infecções agudas de trato respiratório e analisar as taxas de 
internação e de óbito em crianças submetidas à profilaxia 
com palivizumabe.
Métodos: Coorte prospectiva com 198 crianças menores de 
um ano nascidas antes de 29 semanas de idade gestacional e 
crianças menores de dois anos com cardiopatia hemodinami-
camente instável ou doença pulmonar crônica que receberam 
palivizumabe para profilaxia contra infecções graves pelo vírus 
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sincicial respiratório, em 2008. No período do estudo, em cada 
episódio de infecção aguda do trato respiratório, coletou-se 
aspirado de nasofaringe para identificar vírus sincicial respi-
ratório, adenovírus, parainfluenza 1, 2 e 3, influenza A e B 
por imunofluorescência direta, rinovírus e metapneumovírus 
por reação em cadeia de polimerase precedida de transcriptase 
reversa. Monitoraram-se internações e óbitos nesse grupo.
Resultados: Das 198 crianças acompanhadas, 117 
(59,1%) apresentaram infecções agudas de trato respiratório, 
totalizando 175 episódios. De 76 aspirados de nasofaringe 
coletados na vigência de infecções do trato respiratório, 37 
foram positivos, encontrando-se: rinovírus (75,7%), vírus sin-
cicial respiratório (18,9%), parainfluenza (8,1%), adenovírus 
(2,7%), metapneumovírus (2,7%) e múltiplos agentes em três 
amostras. Das 198 crianças, 48 (24,4%) foram internadas, 
sendo 30 (15,2%) por etiologia não respiratória e 18 (9,1%) 
por problemas respiratórios; entre os 18 casos, um foi por vírus 
sincicial respiratório. Duas crianças evoluíram para óbito, não 
tendo sido identificado o vírus sincicial respiratório. 
Conclusões: Na vigência de profilaxia, observou-se 
frequência baixa de infecções pelo vírus sincicial respiratório 
e baixo índice de hospitalizações, sugerindo benefício da 
profilaxia com palivizumabe. 
Palavras-chave: vírus sinciciais respiratórios; anti-
corpos monoclonais; infecções respiratórias/prevenção & 
controle; lactente.
RESUMEN
Objetivo: Identificar los virus implicados en los cua-
dros de infecciones agudas de trato respiratorio y analizar 
las tasas de internación y de óbito en niños sometidos a la 
profilaxis con palivizumabe.
Métodos: Cohorte prospectiva con 198 niños con menos 
de un año nacidas antes de 29 semanas de edad gestacional 
y niños con menos de dos años con cardiopatía hemodiná-
micamente inestable o enfermedad pulmonar crónica que 
recibieron palivizumabe para profilaxis contra infecciones 
graves por el virus sincitial respiratorio, en 2008. En el 
periodo de estudio, en cada episodio de infección aguda del 
trato respiratorio, se recogió aspirado de nasofaringe para 
identificar virus sincitial respiratorio, adenovirus, parain-
fluenza 1,2 y 3, influenza A y B por técnica del anticuerpo 
fluorescente directa, rinovirus y metapneumovirus por reac-
ción en cadena de la polimerasa precedida por transcriptasa 
inversa. Se monitorean internaciones y óbitos en ese grupo.
Resultados: De los 198 niños seguidos, 117 (59,1%) presen-
taron infecciones agudas de trato respiratorio, totalizando 175 
episodios. De 76 aspirados de nasofaringe recogidos en la vigencia 
de infecciones de trato respiratorio, 37 fueron positivos, encon-
trándose: rinovirus (75,7%), virus sincitial respiratorio (18,9%), 
parainfluenza (8,1%), adenovirus (2,7%), metapneumovirus (2,7%) 
y múltiples agentes en tres muestras. De los 198 niños, 48 (24,4%) 
fueron internados, siendo 30 (15,2%) por etiología no respiratoria y 
18 (9,1%) por problemas respiratorios; entre los 18 casos, uno fue 
por virus sincitial respiratorio. Dos niños evolucionaron a óbito, no 
habiendo sido identificado el virus sincitial respiratorio. 
Conclusiones: En la vigencia de profilaxis, se observó fre-
cuencia baja de infecciones por el virus sincitial respiratorio 
y bajo índice de hospitalizaciones, sugiriendo beneficio de 
la profilaxis con palivizumabe. 
Palabras clave: virus sincitiales respiratorios; 
anticuerpos monoclonales; infecciones respiratorias/
prevención y control; lactante.
Introduction
Respiratory syncytial virus (RSV) is the major cause of acute 
lower respiratory tract infections in children younger than 
2 years of age. It has a global distribution and a seasonal behav-
ior. It is estimated that, worldwide, 33.8 million new episodes of 
acute lower respiratory tract infections by RSV occur annually in 
children under 5 years of age. Among these, about 3.4 million 
require hospitalization and 66 to 199 thousand children evolve 
to death, 99% occurring in developing countries(1).
In general, primary RSV infection evolves as a common 
cold. However, approximately 25% of children under 2 years 
may present, in its first episode, infection of the lower air-
ways, severe respiratory failure, need for ventilatory support, 
and, occasionally, death(2).
Preterm children with chronic pulmonary disease, im-
munocompromised children, and children with heart dis-
eases (particularly cyanotic) present greater risk of severe 
respiratory disease by RSV(3-6). Some environmental factors 
are also associated with higher incidence of RSV infections, 
such as exposure to smoke, attendance at day care centers, 
or household contact with other children(4,5).
In tropical and subtropical countries, the occurrence of 
RSV infections is greater in fall and winter, with significant 
regional variations(7). Epidemiological studies on RSV in the 
Southeast region of Brazil showed that the infection by RSV 
starts in April, with peaks in May and June(2,8). More recent 
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studies conducted in the municipality of São Paulo showed 
that the RSV season occurs from March to July, and it may 
start earlier or last up until August(9,10). 
There is no specific treatment for RSV infection(7,11), and prophy-
laxis with a specific anti-RSV monoclonal antibody (palivizumab) 
is widely recommended for high-risk cases(4-6). Its use demonstrated 
a reduction in the rates of hospitalization by RSV infection (55%), 
hospitalization in ICUs (57%), length of hospital stay (42%), and 
the number of days with need of oxygen by 40%(4,5,12,13). 
Palivizumab is, however, a high cost medication. In Brazil, 
until 2007, many children received this medication after ju-
dicial demands, not always based in technical criteria(14). The 
resolution SS n. 249, from July 13, 2007, from the Health Sec-
retariat of the State of São Paulo(15), made palivizumab freely 
available for SUS (Brazilian public Unified Health System) 
patients who were classified as “highly recommended” by the 
Brazilian Pediatrics Society(5). Some centers were indicated 
by the State Secretariat as a place for the application of the 
palivizumab and the Reference Center for Special Immunobio-
logicals (Centro de Referência para Imunobiológicos Especiais - Crie) 
from Universidade Federal de São Paulo (Unifesp) was the first 
center designed for the municipality of São Paulo. 
In this context, the objectives of the present study were 
to describe the etiology of acute viral respiratory infection in 
children on prophylaxis with palivizumab and to analyze the 
rates of hospitalizations and deaths in this group of children. 
Method
This was a prospective study with infants who received 
palivizumab at the Crie-Unifesp in 2008. The project was 
approved by the Research Ethics Committee of the institu-
tion under n. 0342-08, and the signature of the informed 
consent by parents/guardians was required.
The study included infants with indication of palivizumab 
according to the normative resolution SS n. 249, from July 13, 
2007(15), that is, children younger than 1 year of age, born with 
gestational age lower than 29 weeks, after hospital discharge, 
and children younger than 2 years, with hemodynamically 
unstable cardiopathy or chronic pulmonary disease, who needed 
treatment in the 6 months prior to the period of the RSV season. 
Prophylaxis started in April 2008, including infants who re-
ceived the first dose of palivizumab until the last month of June, 
in the dosage of 15mg/kg, via intramuscular (IM), in the vastus 
lateralis muscle of the thigh, with an interval of 30 days and 
maximum of five doses. The scheduling was performed grouping 
patients twice a week to share the flask of the immunobiological. 
Data on the clinical records of the mother and the child 
and the reason for indication of the anti-RSV prophylaxis 
were collected on the day of the first dose of palivizumab by 
means of a questionnaire applied to the parents, besides the 
analysis of a medical form that indicated the administration 
of the monoclonal antibody.
Patients were followed with monthly visits during all the 
season (April to September), and the parents were instructed 
to communicate the researcher in case the child presented 
acute respiratory tract infection during this period (passive 
vigilance). Furthermore, each patient was contacted by phone 
once a week to search for respiratory intercurrences and hos-
pitalizations (active vigilance) during the entire study period.
The acute respiratory tract infection was defined accord-
ing to the World Health Organization(16) as the presence or 
not of fever, associated to running nose or congestion, sore 
throat, cough, sibilance, tachypnea or respiratory difficulty.
In the presence of acute respiratory symptoms, a nasopha-
ryngeal aspirate (NPA) was collected until the fourth day 
after the start of symptoms for the investigation of the fol-
lowing respiratory viruses: influenza A and B, parainfluenza 
1, 2, and 3, adenovirus, RSV, rhinovirus, and metapneumo-
virus. For these patients, a second questionnaire was applied 
with clinical data on the current respiratory event. 
The RSV hospitalization rate was calculated using 
the rate of hospitalization for respiratory distress, multi-
plied by the number of children testing positive for RSV, 
divided by the number of children hospitalized for respira-
tory infection who underwent collection(13).
The collection of the nasopharyngeal aspirate was conducted 
with probe n. 6 or 8, inserted in the nasopharynx after washing 
with saline solution at 0.9%. The aspirate was placed in a sterile 
flask with 5mL of saline solution at 0.9%. The sample was kept 
under refrigeration at 2-8°C and brought to the Laboratory of 
Virology of the institution in 2 hours maximum. 
The samples were fractionated, and an aliquot was cen-
trifuged to perform the direct immunofluorescence and the 
other, was frozen at -80°C, for molecular testing. We per-
formed direct immunofluorescence for influenza A and B, 
parainfluenza 1, 2 and 3, adenovirus, and RSV, according to 
the Light Diagnostics® Respiratory Screen Kit – Respiratory 
Panel 1 DFA (Chemicon International, Inc.). All samples un-
derwent polymerase chain reaction preceded by reverse tran-
scriptase for rhinovirus and human metapneumovirus(17-19).
Numerical variables with normal distribution were compared 
by Student’s t test and those with abnormal distribution, by 
the Mann-Whitney test. Categorical variables were compared 
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by chi-square or Fisher’s exact test. Statistical analysis were 
performed with the Statistical Package for the Social Sciences 
(SPSS), version 17, and significance was established at p<0.05. 
Results
In 2008, 210 infants underwent prophylaxis with palivi-
zumab at Crie-Unifesp. Among these, nine were excluded 
for not meeting the inclusion criteria, one for not having 
a telephone contact and two because they were transferred 
to another service before the end of the prophylaxis period. 
Thus, a total of 198 infants were included in the study.
The children assessed presented mean gestational age 
of 30.2±5.1 weeks (range of 23.0–41.2), birth weight of 
1,482±900g (range of 450–4,165), median duration of me-
chanical ventilation of 12 days (range of 0-163; Q1 [1st quar-
tile]–Q3 [3rd quartile]: 2–40 days) and remained at the neonatal 
unit for 76±60 days (range of 2–638; Q1-Q3: 48–100 days). 
The mean age range of infants at the moment of inclusion in 
the study was of 8.4±4.9 months, being 52% male. 
Among included children, 142 (71.7%) were born in a private 
hospital and 56 (28.3%), in a public hospital. The median house-
hold budget was of R$ 2,500.00 (range of R$ 300.00-20,000.00; 
Q1-Q3: R$ 1,050.00-5,000.00) with the following social classi-
fication, according to the Brazilian Population Studies Association 
(ABEP - criterion Brazil 2008): class A1 — 5 (2.5%) families; 
A2 — 34 (17.2 %); B1 — 38 (19.2%); B2 — 57 (28.8%); C1 — 
27 (13.6%); C2 — 29 (14.7%) and D — 8 (4.0%) families. 
The median number of adults in the household was equal to 
2 (range of 0–7), of adolescents, 0 (range of 0–2), and of children, 
1 (range of 1–4). The number of households with smokers was 
of 57 (28.8%), with 22 (11.1%) smoking mothers. 
Based of the criteria of indication for palivizumab, 29 
(14.6%) children presented gestational age <29 weeks 
without bronchopulmonary dysplasia; 53 (26.8%) were 
hemodynamically unstable neonates with congenital heart 
disease, 116 (58.6%) presented bronchopulmonary dysplasia, 
and 91 (78.4%) preterm infants with dysplasia presented 
gestational age <29 weeks.
Each child received a median four doses of palivizumab 
(variation of 1–5; Q1-Q3: 3–4 doses), totaling 754 doses, 
using 749.1mL of the immunobiological. Among the 198 
children followed, 45 (22.7%) received five doses of palivi-
zumab, 75 (37.9%) four doses, 75 (37.9%) three doses, 1 
(0.5%) received two doses and 2 (1.0%) received one dose. 
The interval between the doses was less than 35 days in 96.9% 
of cases from the first to the second dose, in 93.3% of cases 
from the second to the third dose, in 78.3% of cases from third 
to fourth dose, and in 60.0% of cases from fourth to fifth dose. 
In relation to clinical events, 117 (59.1%) children 
had at least one episode of respiratory infection, totaling 
175 episodes with a median of 1.0 (range of 0–4; Q1-Q3: 
1–2 episodes/patients) and mean of 1.5 episodes/patient. 
Among respiratory infections, 104 (59.4%) were of the 
upper respiratory tract and 71 (40.6%), of the lower re-
spiratory tract (Figure 1). 
Figure 1 - Incidence of upper respiratory tract infection and lower respiratory tract infection in infants who were on palivizumab 
prophylaxis, from April to September 2008
ILRTI
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175 episodes of respiratory infection
Common cold
92 (88.5%)
Rhinitis
2 (1.9%)
Tonsillitis
2 (1.9%)
Sudden rash
1 (1.0%)
Wheezing
15 (15.5%)
Pneumonia
10 (14.1%) Atelectasis
1 (1.4%)
Whooping 
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1 (1.4%)
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48 (67.6%)
Pneumonias
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104 (59.4%)
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7 (6.7%)
URTI: upper respiratory tract infection; LTRI: lower respiratory tract infection
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Among the children studied, 48 (24.2%) required hospi-
talization, being 30 (15.2%) due to non-respiratory etiology 
and 18 (9.1%) for respiratory problems. Of the 18 admissions 
for respiratory causes, nine (50%) were due to pneumonia and 
nine (50%) for bronchiolitis, and, of these, three progressed 
to pneumonia. The median length of hospitalization for these 
diseases was 9 days (range of 3–28; Q1-Q3: 4–12 days). 
NPAs were collected in 13 (72.2%) of the 18 hospitalized 
cases, of which 11 were negative (six cases of bronchiolitis and five 
cases of pneumonia), in one case RSV was detected (bronchiolitis) 
and, in another, parainfluenza 2 and rhinovirus (bronchiolitis) 
were identified. The RSV hospitalization rate was of 0.7% 
(18/198 versus 1/13), according to calculation described above. 
The comparison between children with and without 
bronchiolitis showed no statistical difference regarding sex, 
birth weight, gestational age, length of stay in the nursery, 
days of mechanical ventilation, attendance at daycare centers, 
and presence of smokers in the household. However, children 
with bronchiolitis had lower rates of breastfeeding (p=0.021) 
and more hospitalizations (p<0.001) (Table1). 
At follow-up, there were two (1%) deaths, one in the 
postoperative period of cardiac surgery (hypoplastic left 
ventricle) and the other after hospitalization for pneumonia 
in a child with congenital heart disease who progressed to 
septic shock. In this patient, nasopharyngeal secretion was 
negative for the viruses surveyed.
Of the 175 episodes of respiratory infection, 76 (43.4%) 
NPAs were collected, being 37 (48.7%) negative; in two pa-
tients, the collected material was insufficient and, in 37 (48.7%), 
at least one virus was detected. The viruses identified are shown 
in Figure 2. Among the seven cases in which RSV was detected, 
two occurred in April, three in May, and two in July. 
Discussion
This is the first Brazilian study that assessed respiratory 
infections and involved viruses in children who received 
RSV prophylaxis with palivizumab. 
Of the 198 children followed during the study period, 
about 60% had at least one episode of respiratory infection, 
Figure 2 - Distribution in percentage of viruses found in nasopharyngeal aspirates in hospitalized and non-hospitalized infants 
with signs of airway infection 
8
44
810 8
3 02 02
8
3
Hospitalized
Rhinovirus RSV Parainfluenza 2 Adenovirus Metapneumovirus Co-infection
Non-hospitalized
RSV: respiratory syncytial virus
With bronchiolitis 
(n=43)
Without bronchiolitis 
(n=155) p-value
Male sex - n (%) 22 (51.2) 81 (52.3) 0.899
Birth weight (g) - mean±SD 1401±870 1505±910 0.507
Gestational age (weeks) - mean±SD 29.7±4.5 30.0±5.0 0.685
Duration of mechanical ventilation (days) - mean±SD 25±27 25±32 0.782
Days in the neonatal unit - mean±SD 76±45 25±32 0.782
Going to daycare - n (%) 3 (7.0) 3 (1.9) 0.088
Presence of smokers at home - n (%) 13 (30.2) 44 (28.4) 0.813
Breastfeeding - n (%) 34 (79.1) 142 (91.6) 0.021
Hospitalization after discharge from the neonatal unit - n (%) 10 (23.3) 8 (5.2) <0.001
Table 1 - Demographic and clinical characteristics of the subjects, according to the presence of a diagnosis of bronchiolitis
SD: standard deviation
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with a prevalence of acute infections of the upper respiratory 
tract, being the common cold the most frequent one. Bron-
chiolitis was the most frequent lower respiratory tract infec-
tion. Regarding the NPA samples collected in the presence 
of respiratory infection, in half of the cases some sort of virus 
was detected, being the rhinovirus the most frequent, followed 
by the RSV. In the cases where rhinovirus was identified, 
about 1/3 presented acute lower respiratory tract infections 
with wheezing episode, confirming the literature data(20) that 
show the rhinovirus as an important cause of wheezing in 
children under 2 years old. Of the seven children with RSV, 
six (85.7%) had bronchiolitis and one, a common cold. No case 
of influenza was detected. Children over 6 months and their 
parents received the influenza vaccine in the season evaluated.
Among children hospitalized for respiratory infection, we 
observed a low rate of hospitalization for rhinovirus, and only 
one case of bronchiolitis with rhinovirus coinfection and 
parainfluenza 2, unlike what was reported by Piotrowska 
et al, who found a hospitalization rate of 55% among cases 
where rhinovirus was detected(21). 
Studies on the incidence of RSV include children with a 
wide variability in age, region, community, or hospital popula-
tion. This fact, coupled with the lack of Brazilian studies with 
cohorts of children at high risk for use of palivizumab, hinders 
the comparison with the data found in this investigation.
In this study, the rate of hospitalization for respiratory dis-
ease in children who received palivizumab was 9.1% and the 
rate of hospitalization for RSV was of 0.7%. These data show 
low rates of RSV hospitalization in the cohort who received 
palivizumab, compared with studies in children at high risk 
for severe RSV infection without prophylaxis. A classic mul-
ticenter study with preterm infants at high risk observed a 
rate of hospitalization for RSV of 10.6% in the group without 
prophylaxis, with a 55% reduction in these rates on the group 
with prophylaxis(12). In another study with children under 
2 years with congenital heart disease with hemodynamic 
consequences and not receiving prophylaxis, the rate of hos-
pitalization for RSV was of 9.7%(3). When analyzing studies 
of high-risk children who received palivizumab, our findings 
are comparable. Boivin et al(22) found hospitalization rates of 
12.9% for acute respiratory tract infections and 0.9% for RSV 
in a group of children on prophylaxis with palivizumab. Paes 
et al(23), who analyzed children on palivizumab from 2005 to 
2012 in Canada, observed a rate of hospitalization for acute 
respiratory tract infections of 6.6% and, for RSV, of 1.5%. 
In this study, the cases of infection by RSV occurred between 
April and July. Epidemiologic data show that, in São Paulo, 
when the prophylaxis was initiated in April, the RSV was al-
ready in circulation, what suggests that the prophylaxis should 
be initiated earlier. Also, studies with children hospitalized in 
the municipality of São Paulo showed increased frequency of 
RSV infections from March to July(9,10). Among the 198 children 
followed, 98.5% received three or more doses of palivizumab, 
with an adequate interval between the doses until the third dose. 
However, there was a delay, on average, of 6.6 days (range of 
1–15) in the interval between the fourth and fifth doses, due to 
delay in the supply of palivizumab by the Heath Department of 
the state of São Paulo in August. Children who were discharged 
form the neonatal unit after the beginning of the season received 
a lower number of doses, as well as those who were hospital-
ized during the period of prophylaxis, once palivizumab was 
available only for children who were not hospitalized. Thus, if 
prophylaxis with palivizumab were initiated at the correct sea-
son also for preterm infants hospitalized in the neonatal unit, as 
recommended by the Brazilian Society of Pediatrics(24), children 
could have received a greater number of doses. 
The optimization strategy of the administration of 
palivizumab with grouped scheduling led to an economy 
of 28.2%, with the use of 749.1mL of palivizumab, in 
comparison to 1,044mL that would have been used in case 
of individual scheduling(25). 
Despite having included many children, it was observed 
that most came from private services, probably due to in-
creased access to information of these families and of the pri-
vate services, showing the need to improve the dissemination 
of the program in all health services. This was the first year 
of RSV prophylaxis in the state of São Paulo and, according 
to data of the Immunization Division of the Health Depart-
ment of the State of São Paulo, in 2010, the absolute number 
of patients enrolled in the program nearly doubled, with an 
equitable origin between public and private services(26).
In May 2013, a new decree from the Health Ministry approved 
the protocol for the use of palivizumab in the entire national 
territory, respecting the seasonal differences of each region. Tar-
geted children were preterm infants with less than 1 year old, 
born with gestational age lower or equal to 28 weeks, besides 
children with up to 2 years old with chronic pulmonary disease 
or congenital heart disease with proved hemodynamic repercus-
sion. They also included hospitalized children, administering 
palivizumab, in these cases, in the hospital environment(27).
 The lack of a control group was a limitation of this study; 
however, it would be unethical to include a group of children 
of the same age range, with similar characteristics, without 
providing the monoclonal antibody. It was also not possible to 
158
Respiratory infections in children up to two years of age on prophylaxis with palivizumab
Rev Paul Pediatr 2014;32(2):152-8.
References
1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al. Global 
burden of acute lower respiratory infections due to respiratory syncytial virus in 
young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55. 
2. Vieira SE, Stewien KE, Queiroz DA, Durigon EL, Török TJ, Anderson LA et al. 
Clinical patterns and seasonal trends in respiratory syncytial virus hospitalizations 
in São Paulo, Brazil. Rev Inst Med Trop Sao Paulo 2001;43:125-31.
3. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr et al. 
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial 
virus in young children with hemodynamically significant congenital heart 
disease. J Pediatr 2003;143:532-40.
4. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering 
LK, Baker CJ, Kimberlin DW, Long SS, editors. Red Book: 2009. Report of 
the Committee on Infectious Diseases. 28th ed. Elk Grove Village: American 
Academy of Pediatrics; 2009. p. 560-8.
5. Sociedade Brasileira de Pediatria [homepage on the Internet]. São Paulo: 
Recomendações para prevenção da doença respiratória grave por vírus 
sincicial respiratório [cited 2008 Feb 1]. Available from: http://www.sbp.com.
br/show_item.cfm?id_categoria=89
6. National Advisory Committee on Immunization. Statement on the recommended 
use of monoclonal anti-RSV antibody (palivizumab). Can Commun Dis Rep 
2003;29:1-15.
7. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: 
past, present, and future. Pediatr Pulmonol 2011;46:324-47. 
8. Thomazelli LM, Vieira S, Leal AL, Sousa TS, Oliveira DB, Golono MA et al. 
Surveillance of eight respiratory viruses in clinical samples of pediatric patients 
in southeast Brazil. J Pediatr (Rio J) 2007;83:422-8.
9. Vieira SE, Gilio AE, Durigon EL, Ejzenberg B. Lower respiratory tract infection 
caused by respiratory syncytial virus in infants: the role played by specific 
antibodies. Clinics (São Paulo) 2007;62:709-16. 
10. Pecchini R, Berezin EN, Felício MC, Passos SD, Souza MC, Lima LR et al. 
Incidence and clinical characteristics of the infection by the respiratory syncytial 
virus in children admitted in Santa Casa de São Paulo Hospital. Braz J Infect 
Dis 2008;12:476-9.
11. Bialy L, Foisy M, Smith M, Fernandes RM. The cochrane library and the 
treatment of bronchiolitis in children: an overview of reviews. Evid Based Child 
Health 2011;6:258-75.
12. Autoria não referida. Palivizumab, a humanized respiratory syncytial virus 
monoclonal antibody, reduces hospitalization from respiratory syncytial virus 
infection in high-risk infants. Pediatrics 1998;102:531-7. 
13. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group. 
Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus 
hospitalization in premature infants. Pediatr Infect Dis J 2003;22:823-7.
14. Weckx LY, Loekmanwidjaja J. Profilaxia da infecção por vírus sincicial 
respiratório com uso de palivizumabe: análise da experiência do Crie-Unifesp. 
Proceedings of the XVI Congresso de Iniciação Científica da Universidade 
Federal de São Paulo – PIBIC; 2008 Jun 17-19; São Paulo, Brasil. p. 321. 
15. São Paulo - Secretaria da Saúde do Estado de São Paulo. Resolução 
SS - SP nº 249, de  13 de Julho de 2007. Aprova Norma Técnica relativa 
às diretrizes para a prevenção da infecção pelo vírus sincicial respiratório. 
São Paulo: Diário Oficial do Estado; 2007. Available from: http://www.cremesp.
org.br/?siteAcao=PesquisaLegislacao&dif=s&ficha=1&id=7334&tipo=RES
OLU%C3%87%C3%83O&orgao=Secretaria%20de%20Estado%20da%20
Sa%C3%BAde%20de%20S%C3%A3o%20Paulo&numero=249&situacao=
VIGENTE&data=13-07-2007
16. World Health Organization [homepage on the Internet]. Infection prevention and 
control of epidemic- and pandemic-prone acute respiratory diseases in health 
care [cited 2008 Feb 1]. Available from: http://www.who.int/csr/resources/
publications/WHO_CDS_EPR_2007_6c.pdf
17. Arruda E, Pitkäranta A, Witek TJ, Doyle CA, Hayden FG. Frequency and 
natural history of rhinovirus infections in adults during autumn. J Clin Microbiol 
1997;35:2864-8.
18. Carraro E, Neto DF, Benfica D, SittaPerosa AH, Granato CF, Bellei NC. 
Applications of a duplex reverse transcription polymerase chain reaction 
and direct immunofluorescence assay in comparison with virus isolation for 
detection of influenza A and B. Diagn Microbiol Infect Dis 2007;57:53-7.
19. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus 
infections in young and elderly adults. J Infect Dis 2003;187:785-90.
20. Checon RE, Siqueira MM, Lugon AK, Portes S, Dietze R. Short report: seasonal 
pattern of respiratory syncytial virus in a region with a tropical climate in 
southeastern Brazil. Am J Trop Med Hyg 2002;67:490-1.
21. Piotrowska Z, Vázquez M, Shapiro ED, Weibel C, Ferguson D, Landry ML et al. 
Rhinoviruses are a major cause of wheezing and hospitalization in children 
less than 2 years of age. Pediatr Infect Dis J 2009;28:25-9.
22. Boivin G, Caouette G, Frenette L, Carbonneau J, Ouakki M, De Serres G. 
Human respiratory syncytial virus and other viral infections in infants receiving 
palivizumab. J Clin Virol 2008;42:52-7.
23. Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL. Respiratory-related 
hospitalizations following prophylaxis in the Canadian registry for palivizumab 
(2005-2012) compared to other international registries. Clin Dev Immunol 
2013;2013:917068.
24. Sociedade Brasileira de Pediatria [homepage on the Internet]. São Paulo: 
Diretrizes para o manejo da infecção causada pelo vírus sincicial respiratório 
(VSR) [cited 2013 Jun 14]. Available from: http://www.sbp.com.br/pdfs/
diretrizes_manejo_infec_vsr_versao_final1.pdf
25. Weckx LY, Fernandes MM, Monteiro AI, Souza AR, Moraes-Pinto MI. 
Optimization strategy to minimize wastage of palivizumab during the 2008 
RSV season in São Paulo, Brazil. J Trop Pediatr 2009;55:341-2.
26. Brasil - Ministério da Saúde. Resolução SS nº 249, de 13 de julho de 2007. 
Uso profilático do palivizumabe em crianças de alto risco para doença por 
vírus sincicial respiratório. Ações da Secretaria de Estado da Saúde de São 
Paulo 2007-12. Brasília: Ministério da Saúde; 2007.
27. Brasil - Ministério da Saúde - Secretaria de Atenção à Saúde [homepage 
on the Internet]. Portaria nº 522, de 13 de maio de 2013. Aprova o 
protocolo de uso do palivizumabe. Brasília: Diário Oficial da União; 2013 
[cited 2014 Feb 22]. Available from: http://bvsms.saude.gov.br/bvs/
saudelegis/sas/2013/prt0522_13_05_2013.html
collect NPA from all cases of respiratory infections, especially 
in cases of acute infections of the upper respiratory tract. There 
was a limitation in performing laboratory tests on weekends, 
hampering collection, especially in cases of short-duration 
respiratory infections or because of family travel.
Therefore, in seasons of high circulation of RSV, the palivi-
zumab prophylaxis program in high-risk children showed low 
frequency of RSV infections, with a low rate of hospitalization 
and no deaths by this agent, what suggests the advantage 
of the palivizumab prophylaxis. In children treated with 
palivizumab, the main isolated virus in acute respiratory tract 
infections was the rhinovirus, with high rates of wheezing and 
low hospitalization rates, followed by RSV.
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